A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

Inclusion Criteria: * Healthy male and female subjects aged 18 to 55 years * Informed consent document signed by the subject or a legally acceptable representative * Subjects who are willing and able to comply with the scheduled visits, treatment tests, laboratory tests, and other study procedures Exclusion Criteria: * Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic psychiatric, neurologic or allergic disease or clinical findings at screening * Conditions possibly affecting drug absorption * 12-lead ECg demonstrating QTc \> 450ms or any other clinically significant abnormalities at screen * Positive urine drug screen * Hypersensitivity to moxifloxacin or PF00610335 * Unwilling or unable to comply with the lifestyle guidelines in the protocol Treatment with an investigational drug within 3 months or 5 half lives (whichever is longer) preceding the first dose of study medication